Table 3 List of preclinical studies and clinical trials testing the efficacy of magnetic nanoparticles in targeting solid tumors
From: Nanomedicine for autophagy modulation in cancer therapy: a clinical perspective
Therapeutic name | Mechanism of action | Delivery system | Target(s) | Cancer type | Phase | NCT ID |
|---|---|---|---|---|---|---|
MNPs-DOX | Antimitotic and cytotoxic activity | mNPs + pseudopeptide NucAnt(N6L) | DNA of tumor cells | Breast cancer (mice) | preclinical | – |
MNPs-GEM | Nucleoside metabolic inhibitor | mNPs | DNA of tumor cells | Pancreatic cancer (PANC-1 cells) | preclinical | – |
NanoTherm®therapy | Magnetic field hyperthermia in combination with gemcitabine and nab-paclitaxel | mNPs + Albumin | DNA of tumor cells | Prostate | I | NTC02033447 |
NanoTherm®therapy | Magnetic field hyperthermia in combination with gemcitabine and nab-paclitaxel | mNPs + Albumin | DNA of tumor cells | Glioblastoma | I | DKRS00005476 |